Ensiklopedia Dunia

Everolimus
Data klinis
Pengucapan	Everolimus /ˌɛvəˈroʊləməs/
Nama dagang	Afinitor, Certican, Everonat, Zortress
Nama lain	42-O-(2-hidroksietil)rapamisin, RAD001
AHFS/Drugs.com	monograph
MedlinePlus	a609032
License data	US DailyMed: Everolimus;
Kategori; kehamilan	AU: C ; ;
Rute; pemberian	Oral
Kode ATC	L01EG02 (WHO) L04AH02;
Status hukum
Status hukum	AU: S4 (Prescription only) ; UK: ; US: ℞-only ; EU: Rx-only ; ℞ (Hanya resep);
Data farmakokinetika
Waktu paruh eliminasi	~30 jam
Pengenal
	Nama IUPAC Dihidroksi-12-[(2R)-1-[(1S,3R,4R)-4-(2-hidroksietoksi)-3-metoksisikloheksil]propan-2-il]-19,30-dimetoksi-15,17,21,23,29,35-heksametil-11,36-dioksa-4-azatrisiklo[30.3.1.0 heksatriakonta-16,24,26,28-tetraena-2,3,10,14,20-pentona;
Nomor CAS	159351-69-6 ;
PubChem CID	6442177;
DrugBank	DB01590 ;
ChemSpider	21106307 ;
UNII	9HW64Q8G6G;
KEGG	D02714 ;
ChEBI	CHEBI:68478;
ChEMBL	ChEMBL1908360 ;
CompTox Dashboard (EPA)	DTXSID0040599 ;
ECHA InfoCard	100.149.896
Data sifat kimia dan fisik
Rumus	C53H83NO14
Massa molar	958,24 g·mol−1
Model 3D (JSmol)	Gambar interaktif;
	SMILES OCCO[C@@H]1CC[C@H](C[C@H]1OC)C[C@@H](C)[C@@H]4CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N3CCCC[C@H]3C(=O)O4;
	InChI InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1 ; Key:HKVAMNSJSFKALM-GKUWKFKPSA-N ;
	(what is this?) (verify)

Everolimus adalah obat yang digunakan sebagai imunosupresan untuk mencegah penolakan transplantasi organ^[9] dan sebagai terapi bertarget dalam pengobatan kanker sel ginjal dan tumor lainnya.^[10]

Obat ini adalah turunan 40-O-(2-hidroksietil) dari sirolimus dan bekerja serupa dengan sirolimus sebagai penghambat target rapamisin manusia dan mamalia.^[11]

Obat ini tercantum dalam Daftar Obat Esensial Organisasi Kesehatan Dunia.^[12] Obat ini tersedia sebagai obat generik.^[13]

Referensi

^
^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Diakses tanggal 30 March 2024.
^ "Summary of Product Characteristics (SmPC) - (emc)". Certican Tablets. 15 January 2021. Diakses tanggal 30 December 2021.
^ "Afinitor- everolimus tablet Afinitor Disperz- everolimus tablet, for suspension". DailyMed. Diakses tanggal 30 December 2021.
^ "Zortress- everolimus tablet". DailyMed. Diakses tanggal 30 December 2021.
^ "Afinitor EPAR". European Medicines Agency. 17 September 2018. Diakses tanggal 30 December 2021.
^ "Votubia EPAR". European Medicines Agency. 17 September 2018. Diakses tanggal 30 December 2021.
^ Formica RN, Lorber KM, Friedman AL, Bia MJ, Lakkis F, Smith JD, Lorber MI (March 2004). "The evolving experience using everolimus in clinical transplantation". Transplantation Proceedings. 36 (2 Suppl): 495S – 499S. doi:10.1016/j.transproceed.2004.01.015. PMID 15041395.
^ Tedesco-Silva H, Saliba F, Barten MJ, De Simone P, Potena L, Gottlieb J, Gawai A, Bernhardt P, Pascual J (January 2022). "An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients". Transplantation Reviews. 36 (1) 100655. Orlando, Fla. doi:10.1016/j.trre.2021.100655. hdl:10230/53730. PMID 34696930. S2CID 239887236.
^ Hasskarl J (2018). "Everolimus". Small Molecules in Oncology. Recent Results in Cancer Research. Vol. 211. hlm. 101–123. doi:10.1007/978-3-319-91442-8_8. ISBN 978-3-319-91441-1. PMID 30069763.
^ Hasskarl J (2018). "Everolimus". Dalam Martens UM (ed.). Small Molecules in Oncology (Edisi Third). Heidelberg: Springer. hlm. 101–124. ISBN 978-3-319-91442-8.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^ "First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 15 November 2021. Diarsipkan dari asli tanggal 12 June 2019. Diakses tanggal 30 December 2021.

Bacaan lebih lanjut

Sedrani R, Cottens S, Kallen J, Schuler W (August 1998). "Chemical modification of rapamycin: the discovery of SDZ RAD". Transplantation Proceedings. 30 (5): 2192–2194. doi:10.1016/S0041-1345(98)00587-9. PMID 9723437.

[Drugs.com_pregnancy-1] ^

[2] "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Diakses tanggal 30 March 2024.

[3] "Summary of Product Characteristics (SmPC) - (emc)". Certican Tablets. 15 January 2021. Diakses tanggal 30 December 2021.

[Afinitor_FDA_label-4] "Afinitor- everolimus tablet Afinitor Disperz- everolimus tablet, for suspension". DailyMed. Diakses tanggal 30 December 2021.

[Zortress_FDA_label-5] "Zortress- everolimus tablet". DailyMed. Diakses tanggal 30 December 2021.

[Afinitor_EPAR-6] "Afinitor EPAR". European Medicines Agency. 17 September 2018. Diakses tanggal 30 December 2021.

[Votubia_EPAR-7] "Votubia EPAR". European Medicines Agency. 17 September 2018. Diakses tanggal 30 December 2021.

[8] Formica RN, Lorber KM, Friedman AL, Bia MJ, Lakkis F, Smith JD, Lorber MI (March 2004). "The evolving experience using everolimus in clinical transplantation". Transplantation Proceedings. 36 (2 Suppl): 495S – 499S. doi:10.1016/j.transproceed.2004.01.015. PMID 15041395.

[TedescoSilva_2022-9] Tedesco-Silva H, Saliba F, Barten MJ, De Simone P, Potena L, Gottlieb J, Gawai A, Bernhardt P, Pascual J (January 2022). "An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients". Transplantation Reviews. 36 (1) 100655. Orlando, Fla. doi:10.1016/j.trre.2021.100655. hdl:10230/53730. PMID 34696930. S2CID 239887236.

[Hasskarl_2018-10] Hasskarl J (2018). "Everolimus". Small Molecules in Oncology. Recent Results in Cancer Research. Vol. 211. hlm. 101–123. doi:10.1007/978-3-319-91442-8_8. ISBN 978-3-319-91441-1. PMID 30069763.

[11] Hasskarl J (2018). "Everolimus". Dalam Martens UM (ed.). Small Molecules in Oncology (Edisi Third). Heidelberg: Springer. hlm. 101–124. ISBN 978-3-319-91442-8.

[World_Health_Organization_2023-12] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[13] "First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 15 November 2021. Diarsipkan dari asli tanggal 12 June 2019. Diakses tanggal 30 December 2021.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

Ensiklopedia Dunia

Everolimus

Referensi

Bacaan lebih lanjut

Beranda

Program Studi